Several biomarkers that are overexpressed in activated HSCs—such as retinol-binding protein (RBPR), insulin growth factor 2 receptor (IGF2R), platelet-derived growth factor receptor-beta (PDGFR-β), and low-density lipoprotein receptor (LDLR)—have been used to target therapeutic agents to activated HSCs for the treatment of liver fibrosis [19]. Here, LDLR is linked to Hepatic fibrosis.